Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Beam Therapeutics Inc. (BEAM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of BEAM-201 in T-ALL/T-LL and Expected to be Dosed in The Third Quarter of 2023 Company to Accelerate Development of BEAM-302 for Treatment of AATD; Program Now Expected to be First In Vivo Liver Regulatory Filing in First Quarter of 2024 Well-Capitalized with $1.1B in Cash, Cash Equivalents and Marketable Securities at the End of the Second Quarter of 2023 CAMBRIDGE, Mass., August 8, 2023"
07/21/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/10/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amendment No. 2 to Sales Agreement, by and between Beam Therapeutics Inc. and Jefferies LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to Beam Therapeutics Inc"
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites Activated and Additional Patients Enrolled in BEACON Clinical Trial of BEAM-101 for Patients with Sickle Cell Disease Twenty-Year Industry Veteran, Gopi Shanker, Ph.D., Appointed as Chief Scientific Officer Well-Capitalized with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities at the End of the First Quarter of 2023 CAMBRIDGE, Mass., May 10, 2023"
04/21/2023 ARS Form ARS - Annual Report to Security Holders:
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2023 SC 13G Temasek Holdings Ltd reports a 5% stake in Beam Therapeutics Inc.
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Temasek Holdings Ltd reports a 4.1% stake in Beam Therapeutics Inc.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8.9% stake in Beam Therapeutics Inc.
02/09/2023 SC 13G/A FMR LLC reports a 11% stake in BEAM THERAPEUTICS INC
02/02/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Beam Therapeutics Inc. Corporate Presentation",
"Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones"
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Deficiency; Targeting Durable Gene Correction Designed to Address Both Lung and Liver Disease New Data Highlighting Enhanced Conditioning Approach for Hematologic Transplant to be Presented at ASH Ended Third Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities CAMBRIDGE, Mass., November 7, 2022 – Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines t..."
09/07/2022 8-K Other Events  Interactive Data
08/30/2022 8-K Other Events  Interactive Data
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
08/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application CAMBRIDGE, Mass., August 1, 2022 –"
07/14/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/10/2022 8-K Quarterly results
05/09/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/09/2022 8-K Quarterly results
04/22/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy